Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

[1]  T. Dodson,et al.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[2]  S. Taneja.  Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2014, The Journal of urology.

[3]  W. Gradishar,et al.  Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Gilbert,et al.  Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Saad,et al.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Sereika,et al.  Long‐term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study , 2013, The breast journal.

[7]  D. Solomon,et al.  Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta‐analysis , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  A. Brufsky.  Precision Oncology in Breast Cancer: Better than Ever, or Less than Before? , 2013, The breast journal.

[9]  D. Amadori,et al.  Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. , 2013, The Lancet. Oncology.

[10]  N. Binkley,et al.  A case of an unusual subtrochanteric fracture in a patient receiving denosumab. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[11]  F. Saad,et al.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.

[12]  C. Grimsrud,et al.  Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. , 2012, Bone.

[13]  L. Hayward,et al.  Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. , 2012 .

[14]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Pérez-Ruixo,et al.  Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors , 2012, Clinical Cancer Research.

[16]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[17]  G. Block,et al.  A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  L. Fallowfield,et al.  P4-13-01: Pain Severity and Analgesic Use Associated with Skeletal-Related Events in Patients with Advanced Breast Cancer and Bone Metastases. , 2011 .

[19]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[20]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. Saad,et al.  Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors , 2010, Cancer investigation.

[22]  J. Gralow,et al.  Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  M. Kris,et al.  Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  X. Mariette,et al.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Hortobagyi,et al.  Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  N. Watts,et al.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.

[27]  D. Felsenberg,et al.  Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease , 2007, Nature Clinical Practice Oncology.

[28]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[29]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[30]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.